clinical trial · NCT05090904
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Cystic FibrosisBrensocatibPlacebo
brief summary
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.
started
Nov 30, 2021
primary completion
Nov 1, 2022
completion
Nov 1, 2022
last updated
Mar 12, 2026
official title
A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol